Our client’s challenge
Crohn’s Disease (CD) is a common but chronic form of inflammatory bowel disease (IBD) with a high prevalence in Australia. Persistence to CD treatment, the time from initiation to discontinuation or switch of therapy, is key to providing successful long-term treatment outcomes in CD. However, in Australia, real-world evidence to support CD treatment practice is limited.1
Our client’s brand, an anti-IL12 and anti-IL23 monoclonal antibody (Drug A), is indicated for the treatment of adults with moderate to severe active CD who are not responding to or have medical contraindications to either conventional therapy or TNFα antagonists. Drug A was to be the first biological therapy for severe CD subsidised by the Australian government’s Pharmaceutical Benefits Scheme (PBS) in several years. Our client wanted to understand the real-world treatment persistence patterns, in particular, how patients prescribed biologics progressed with their treatment over a 12-month period and their reasons for discontinuation.1
……………. Download full case study here: https://tinyurl.com/yb5x423j
Speak to Prospection today to learn more about about the Prospection platform and its analytics capabilities.
